| Followers | 832 |
| Posts | 119787 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Tuesday, November 11, 2008 11:28:07 AM
2009 Clinical and Preclinical Goals
The top chart is from today’s Rodman & Renshaw
webcast, and the bottom chart is from the Collins
Stewart webcast on 9-Jul-2008.
What has changed? Several things:
1. The ATryn phase-2 DIC trial, which had been expected to wrap up in mid 2009, is now expected to drag into 2010 (and possibly beyond).
2. Canadian approval of ATryn is no longer being sought. (This is not surprising inasmuch as LFB has no presence in Canada.)
3. The start of phase-1 for AAT has been pushed back from late 2009 to early 2010.
4. The CD137 program is no longer shown on the chart and has presumably been moved to the back burner.
The top chart is from today’s Rodman & Renshaw
webcast, and the bottom chart is from the Collins
Stewart webcast on 9-Jul-2008.
What has changed? Several things:
1. The ATryn phase-2 DIC trial, which had been expected to wrap up in mid 2009, is now expected to drag into 2010 (and possibly beyond).
2. Canadian approval of ATryn is no longer being sought. (This is not surprising inasmuch as LFB has no presence in Canada.)
3. The start of phase-1 for AAT has been pushed back from late 2009 to early 2010.
4. The CD137 program is no longer shown on the chart and has presumably been moved to the back burner.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
